Purified bovine brain G-protein was used in a solution phase assay to identify membrane-associated proteins that influenced the activation of heterotrimeric G-proteins. Detergent-solubilized membrane extracts from the neuroblastoma-glioma cell hybrid NG108-15, but not the parent C6B4 glioma cell line, increased [
Two key steps in the propagation of signals across the cell membrane and within the cell are the exchange of GDP for GTP and the subsequent hydrolysis of GTP by guanine nucleotidebinding proteins (1) (2) (3) (4) . Due to the central place of these events in signal propagation, several mechanisms have evolved to initiate and terminate the G-protein activation cycle. For heterotrimeric G-proteins, binding of agonist to a heptahelical receptor is a trigger for guanine nucleotide exchange. However, the efficiency of this process varies among cell types (5, 6) , prompting suggestions that signaling specificity/efficiency for receptors coupled to heterotrimeric guanine nucleotide-binding proteins is engineered in part by accessory proteins operating within the receptor's microenvironment.
Both the heterotrimeric and monomeric G-protein signaling systems are likely to operate within a signal transduction complex, which is either preexisting or is generated by the biological stimuli. The components of such a signaling complex are unclear, particularly for systems using the heterotrimeric Gprotein family. In addition to receptor and effector, there may be additional proteins that influence events at the receptor-Gprotein or G-protein-effector interface and regulate the key steps of nucleotide exchange and/or GTP hydrolysis (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) . Such accessory proteins include kinases, arrestins, and phosphatases that influence receptor coupling to G-protein, as well as unknown entities that together with the receptor may contribute to the formation of a signal transduction complex on the inner face of the plasma membrane. Such proteins may influence the "direction" or strength of the agonist-induced signal or may also act independently of receptor to influence the activation state of G-protein. Examples of such putative entities include neuromodulin, tubulin, caveolin, the yeast protein Sst2p and the egl-10 gene product of Caenorhabditis elegans. The calmodulin-binding protein neuromodulin colocalizes with G o in neuronal growth cones, accelerates binding of nucleotide to G-protein, and is postulated to facilitate the transfer of signal from receptor to G-protein (13, 16 -18) . The activation state of G-protein is also influenced by the cytoskeletal protein tubulin (12, 19, 20) , the wasp venom mastoparan (21) , compound 48/80 (22) , and some types of caveolins (14, 23, 24) , a family of proteins localized to microdomains of the plasma membrane and implicated in cell signaling events. In the present study, we report the characterization of a membrane-associated protein that directly activates G. This G-protein activator is distinct from known proteins that influence nucleotide binding to G-protein and activates G␣ in the presence or absence of G␤␥.
NG108-15 and C6B4 cell lines were grown on Falcon Primeria dishes at 37°C (5% CO 2 ) in Dulbecco's modified Eagle's medium with high glucose (4.5 g/liter), supplemented with 10% fetal bovine serum (NG108-15, C6B4), 100 M hypoxanthine (NG108-15), 0.4 M aminopterine (NG108-15), 16 M thymidine (NG108-15) plus penicillin (100 units/ml), streptomycin (100 g/ml), and fungizone (0.25 g/ml). Membranes, prepared as described (10) , were solubilized with 1% detergent (detergent:protein ratio of 2:1) in buffer A (50 mM Tris-HCl, pH 7.4, 5 mM MgCl 2 , 0.6 mM EDTA) with stirring at 4°C for 60 min. The solubilized membrane extract was isolated by centrifugation at 100,000 ϫ g for 1 h. Using the detergent Thesit, approximately 40% of membrane protein was solubilized under these conditions. The biophysical and structural properties of the G-protein activator were determined using DEAE ion exchange chromatography, gel filtration, and a lectin affinity matrix. Solubilized membrane proteins (10 -20 mg of protein in 5-10 ml) were applied (0.8 ml/min) to a column (0.8 ϫ 6.25 cm) of DEAE-agarose (DEAE Bio-Gel A gel) equilibrated with 20 column volumes of buffer A containing 0.1% Thesit, followed by washing with the same buffer containing 10 mM NaCl until the optical density of the effluent was zero. Proteins retained on the resin were eluted with a linear gradient of 10 -100 mM NaCl (0.8 ml/min, gradient volume ϭ 50 ml) in buffer A containing 0.1% Thesit; 1.6-ml fractions were collected.
Peak activity fractions eluted from DEAE ion exchange resins were concentrated in a Centricon concentrator (Amicon, Beverly, MA) (molecular weight cutoff ϭ ϳ100,000) and further fractionated by gel filtration using BioGel A-0.5m (fractionation size ϳ10,000 -500,000). Samples (1.5 ml, ϳ300 -800 g of protein) were applied to size exclusion columns (1.5 ϫ 93 cm) at a flow rate of 0.1 ml/min (1-ml fractions collected), and proteins were eluted with buffer A containing 0.1% Thesit and 100 mM NaCl. The void volume (V 0 ) of the column was determined using blue dextran, and the separation properties of the resin were evaluated by determining the V e of sizing standards. The collected fractions were assayed for bioactivity and protein amounts. Aliquots (80 l, ϳ10 -15 g of protein) of the peak activity fraction from a size exclusion column were incubated with a wheat germ agglutinin (WGA) lectin affinity matrix (20 -25 l) for 2 h at 4°C. The resin was washed with 2 ϫ 500 l of buffer A containing 0.1% Thesit and retained proteins eluted by incubation (3 h, 4°C) with the same buffer (80 l) containing 500 mM N-acetylglucosamine. Protein concentrations in the samples eluted from the size exclusion resin were determined by the Micro BCA assay system (Pierce), by Coomassie Blue staining following denaturing polyacrylamide gel electrophoresis, and by Amido Black staining of nitrocellulose spotted with aliquots of sample and known amounts of standard protein to provide internal consistency in the calculation. Protein concentrations of the fractions eluted from the WGA lectin affinity resin were estimated by the latter procedure.
Guanine Nucleotide Binding-Binding of [ 35 S]GTP␥S to purified bovine brain G-protein (26 -28) was determined as described previously (5) . Greater than 95% of the isolated brain G-protein binds the nonhydrolyzable analog of guanosine triphosphate GTP␥S, and approximately 85% of the G-protein population corresponds to G o . The standard assay system was as follows. A preincubation mixture was prepared for each assay point. Nonspecific binding was defined with 100 M GTP␥S. Unless indicated otherwise, the final concentration of GDP was 1 M. The preincubation mixture consisted of brain G-protein, GDP, and other components in buffer A (50 mM Tris-HCl, pH 7.4, 5 mM MgCl 2 , 0.6 mM EDTA). The concentrations of brain G-protein and GDP in the preincubation mixture were 5 times the final concentration desired in the assay tube. After a 1-h incubation of the preincubation mixture at 4°C, 10 l of the mixture was added to the assay tube containing buffer A plus (final concentrations) 150 mM NaCl, 1 mM dithiothreitol, ϳ230,000 cpm (ϳ2 nM) [
35 S]GTP␥S, vehicle or 100 M GTP␥S (total volume ϭ 50 l). Unless indicated otherwise, samples were incubated at 24°C for 30 min. In studies concerned with the initial rate of [ 35 S]GTP␥S binding to G-protein, samples were preincubated with extract as described above and then added to the assay tube as above, except that the tube contained increasing amounts of GTP␥S and incubation was at 24°C for 5 s to 5 min. The desired concentration of GTP␥S was obtained by dilution of [
35 S]GTP␥S with the appropriate amount of nonradioactive GTP␥S and the initial rate determined as described previously (29, 30) . Incubated reactions were terminated by rapid filtration through nitrocellulose filters (Scheicher & Schuell BA85) with four 4-ml washes with buffer B (50 mM Tris-HCl, 5 mM MgCl 2 , 1 mM EDTA, pH 7.4, 4°C). Radioactivity bound to the filters was determined by liquid scintillation counting.
Immunoblotting and Immunoprecipitation-Membrane extracts were cleared of neuromodulin by immunoprecipitation using monoclonal antibody clone 91E12. Several preliminary experiments were performed to determine the optimal conditions for antibody concentration, amount of extract, and protein G-Sepharose. Final conditions were as follows. Membrane extract (40 l) was incubated with 15 g of antibody at 4°C for 12 h (0.05% Thesit) before addition of 3 l of protein G-Sepharose beads. After incubation at 4°C for 3 h, protein G-Sepharose beads were pelleted by centrifugation and aliquots of the supernatants were evaluated by immunoblotting and bioactivity assays. The pellets were washed with 1 ml of buffer A containing 0.05% Thesit and prepared for denaturing gel electrophoresis. Immunoblotting was performed as described previously (31) . 35 S]GTP␥S to G-protein is decreased, optimizing the detection of entities that might accelerate nucleotide exchange. Relatively low concentrations of G-protein (0.5-25 nM) and membrane extract protein (1-10 g) were used in the assay system, and [ 35 S]GTP␥S binding to G-protein was evaluated in three sets of tubes for each experiment: 1) sample extract alone, 2) G-protein alone, and 3) sample extract and G-protein following preincubation. Thus, greater or less than additive amounts of nucleotide binding in set 3 compared with the sum of sets 1 and 2 would indicate the presence of a factor that influenced nucleotide binding in a stimulatory or inhibitory manner, respectively. Such a strategy was used previously to demonstrate the existence of a factor in PC-12 cell membrane extracts that increased the amount of [
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35 S]GTP␥S bound to G-protein. This bioactivity was absent in a detergent-solublized extract of membranes prepared from NIH-3T3 fibroblasts (5) . Screening of additional cell lines and tissues indicated that this bioactivity was most abundant in membrane extracts prepared from the neuroblastoma ϫ glioma cell hybrid NG108-15 ( Fig. 1) .
Preincubation of membrane extracts from NG108-15 but not the parent C6B4 cell line increased the binding of nucleotide to bovine brain G-protein by 460% (Fig. 1A) . Nucleotide binding to NG108-15 and C6B4 extracts alone in the absence of G-protein was 2.69 Ϯ 0.021 and 0.62 Ϯ 0.035 fmol, respectively. Under these experimental conditions, ϳ4 fmol of [ 35 S]GTP␥S was bound to G-protein when assayed in the absence of membrane extract. The stimulatory effect of the membrane extract from NG108-15 cells was heat-sensitive and was retained in the concentrate following centrifugation in a YM-30 microconcentrator (fractionation size ϳ30,000 daltons), indicating that this factor is likely a protein rather than a small organic molecule. Several series of experiments were performed to determine optimal conditions for solubilization of the bioactivity from NG108-15 cells. The nonionic detergent Thesit (polyoxyethylene-9-lauryl ether) proved most effective in terms of the total amount of bioactivity extracted and the specific activity of the extract (Fig. 1B) .
The NG108-15 neuroblastoma-glioma hybrid cell line was used as a source for partial purification and characterization of the bioactivity. The solubilized membrane preparation was first fractionated by DEAE ion exchange chromatography (Fig.  2) . The activity was monitored using purified brain G-protein in the solution-phase assay as described above. Under the experimental conditions used, greater than 95% of the bioactivity was retained by the resin. The level of nucleotide binding to eluted fractions in the absence of G-protein ranged from 0.9 to 3.8 fmol. In the set of tubes containing G-protein alone, the level of nucleotide binding was 12.9 fmol. Preincubation of aliquots of eluted fractions with G-protein increased nucleotide binding to G-protein up to 8-fold. The magnitude of the activation of G-protein by the fractionated material was linearly dependent upon the concentration of protein in the assay system (Fig. 3) . Fractionation of the solubilized material by DEAE ion exchange chromatography resulted in a ϳ47-fold increase in specific activity, with a calculated recovery of ϳ100 -150%. 2 Analysis of the eluted fractions by immunoblotting using a G o ␣ antisera that recognizes known G o ␣ isoforms indicated that the bioactivity exhibited an elution profile distinct from that of the general population of G o . 3 Pooled peak activity fractions eluted from DEAE-ion exchange resins were used to characterize the functional, structural, and biophysical properties of the bioactivity. The bioactivity eluted from the ion exchange resin was retained in the concentrate following centrifugation in a YM-100 microconcentrator, and this step (ϳ95% recovery of bioactivity) resulted in an additional increase in specific activity (2-10-fold), which was somewhat dependent on the amount of material processed. Proteins in the concentrated material were further resolved by size exclusion chromatography (Fig. 4) . The peak activity fraction eluted from the size exclusion matrix exhibited a V e /V 0 of 1.2 for the detergent-solubilized complex corresponding to the Stoke's radius of a globular protein with a molecular weight of ϳ246,000 (Fig. 4, inset) . The degree of purification achieved by size exclusion chromatography and the recovery of applied material ranged from 2-to 4-fold and 26 to 45% in five individual experiments using different preparations of membrane ex- 
FIG. 2.
Fractionation of NG108-15 membrane extracts by ionexchange chromatography. NG108-15 cell membranes were solubilized in 1% Thesit (detergent:protein ϭ 2:1) and fractionated by ion exchange chromatography as described under "Experimental Procedures." In this particular experiment, 16 mg of membrane extract was (8 ml) applied to a DEAE-ion exchange column and adsorbed proteins were eluted with a NaCl gradient as indicated in the middle panel. Top panel, elution profile of G o . Eluted fractions (40 l, ϳ2.5-10 g for fractions 6 -34) were electrophoresed on denaturing polyacrylamide gels (10%). The protein concentration of the peak activity fraction was ϳ80 g/ml. Proteins were transferred to nitrocellulose and incubated with antisera against G o (22) . tracts. The bioactivity eluted from the size exclusion resin was retained on a WGA lectin affinity matrix, indicating that the bioactive factor is either glycosylated via N-linked oligosaccharides or else it is tightly associated with such a protein (Fig. 5) . Approximately 60% of the bioactive material retained by the resin was recovered by elution with N-acetylglucosamine.
Relationship to Other G-protein Regulators-Several proteins are known to influence the function of heterotrimeric G-proteins, and it was of interest to determine if the activity Fractions of NG108-15 membrane extract eluted from the DEAE ion-exchange resin containing peak bioactivity (fractions 8 -14) were pooled, and increasing amounts of protein were preincubated with bovine brain G-protein. [ 35 S]GTP␥S (2 nM) binding to bovine brain G-protein (12.5 nM) was determined in the solution phase assay (100 l) as described under "Experimental Procedures." The dilution was corrected to contain a similar amount of detergent for each point. Nucleotide binding to G-protein was not altered by addition of bovine serum albumin (Fraction V) (at protein concentrations equivalent to that found in eluted fraction), indicating that protein concentration of the sample itself was not an interfering factor. [
35 S]GTP␥S binding to membrane extract alone ϭ 0.28 -0.8 fmol. Data are representative of three experiments using different sample preparations.
FIG. 4.
Fractionation of NG108-15 membrane extracts by size exclusion chromatography. Peak bioactivity fractions of NG108-15 membrane extract eluted from a DEAE ion-exchange resin were concentrated and applied to a gel filtration column as described under "Experimental Procedures." Aliquots (4 l) of the eluted fractions were assayed for bioactivity using the solution phase assay (G-protein, 1.25 nM, 50 l). Protein in the eluted fractions were quantitated by the Micro BCA protein assay, Coomassie Blue staining of proteins following denaturing gel electrophoresis, and Amido Black staining of proteins on nitrocellulose blots using standards of known concentration. The protein concentration of the peak activity fraction was ϳ50 -150 g/ml. The elution of sizing standards is indicated by the arrows: blue dextran (ϳ 2,000,000), ferritin (ϳ450,000), catalase (ϳ240,000), aldolase (ϳ158,000), bovine serum albumin (ϳ66,000), hen ovalbumin (ϳ45,000), chymotrypsinogen A (ϳ25,000), cytochrome c oxidase (ϳ12,500). Inset, elution profile of bioactivity (dashed lines) and sizing standards. Similar results were obtained in four experiments using different solubilized preparations.
FIG. 5.
Interaction of NG108-15 membrane extract bioactivity with a lectin affinity matrix. An aliquot (ϳ80 l, ϳ10 g of protein) of the peak activity fraction eluted from a size exclusion column was incubated with the WGA-lectin affinity matrix as described under "Experimental Procedures." Pre-resin, sample prior to incubation with resin. post-resin, sample following incubation with resin. elution, sample obtained following incubation of the resin with 500 mM N-acetylglucosamine. Aliquots (6 l) of the pre-, post-, and eluted samples were assayed for their effects on [
35 S]GTP␥S binding to G-protein (1.25 nM). The protein concentration in the pre-resin material was ϳ125 g/ml, whereas the eluted material contained less than 100 g/ml. The experiment was repeated twice with similar results.
FIG. 6. Effect of membrane extracts on nucleotide binding to G-protein before and after preclearing extract of neuromodulin.
In A and B, NG108-15 and PC-12 cell membranes were solubilized in 1% Thesit (detergent:protein ϭ 2:1) and the extract was assayed for the presence of a G-protein activator before and after reducing the amount of neuromodulin in the extract by immunoprecipitation as described under "Experimental Procedures." A, immunoblot generated with the monoclonal antibody clone 91E12 to neuromodulin (PC-12 extract, 120 g of protein; NG108, 15-60 g of protein; rat brain, 25 g of protein) before and after clearing the NG108-15 and PC-12 extract of neuromodulin. In B, the membrane extract evaluated by immunoblotting in A was analyzed (PC-12, 11 g of protein; NG108-15, 5.5 g of protein) for effects on [
35 S]GTP␥S binding to bovine brain G-protein as described under "Experimental Procedures." Data are presented as the mean of duplicate determinations. Experiments were repeated three times with similar results. In C, the fractions eluted from the DEAE ion exchange resin described in Fig. 2 were evaluated for the presence of neuromodulin by immunoblotting exactly as described for G o in the legend to Fig.  2 . pre, solubilized material applied to the resin. post, sample flowthrough from the resin. characterized above is related to any of these entities. One such protein is neuromodulin or GAP-43, a calmodulin-binding protein that is enriched in neural tissue and increases the binding of [
35 S]GTP␥S to brain G-protein. Neuromodulin is expressed in both NG108-15 and PC-12 cells, where it colocalized with G o . Two approaches were used to indicate that the bioactivity isolated from NG108-15 cells did not correspond to neuromodulin. First, the effect of PC-12 and NG108-15 extract on nucleotide binding to G-protein was compared before and after reducing the amount of neuromodulin in the extract by immunoprecipitation using a monoclonal antibody to neuromodulin. Second, the elution profile of neuromodulin from the DEAE ion exchange column was determined by immunoblotting and compared with that of the peak bioactivity detected in the solution phase assay. As indicated in Fig. 6 (A and B) , the ability of the membrane extract to increase nucleotide binding was not altered by reduction of the amount of neuromodulin in the solubilized extract. In addition, the elution profile of neuromodulin from the ion exchange resin differed from that of the extract bioactivity, clearly indicating that the bioactivity detected under these conditions could not be attributed to neuromodulin (Fig. 6C) . Immunoblot analysis using antibodies for other proteins known to influence nucleotide binding to Gprotein, indicated that the bioactivity was also distinct from caveolin, tubulin, and ␤-amyloid precursor protein (Fig. 7) . This was demonstrated by comparing the immunoreactivity for each protein in the starting material to that found in fractions eluted from the ion exchange resin containing the highest level of bioactivity in our assay system. As the bioactivity appears to represent a novel protein, it is henceforth referred to as a G-protein activator and we further investigated its effects using the pooled peak fractions of bioactivity eluted from the ion exchange resin.
Effect of G-protein Activator on Nucleotide Binding Properties of Bovine Brain G-protein-To gain insight as to the mech-
anism by which the G-protein activator from NG108-15 membranes alters the guanine nucleotide binding properties of brain G-protein, we determined the effect of the partially purified activator on the initial rate of [
35 S]GTP␥S binding to brain G-protein in the presence of added GDP at increasing concentrations of [
35 S]GTP␥S (Fig. 8) . Under the normal incu- FIG. 7 . Immunoblot analysis of peak activity fractions for expression of tubulin, ␤-amyloid precursor protein, and caveolin. Membranes, solubilized membranes, and the fractions of NG108-15 membrane extracts eluted from the ion exchange resin (see Fig. 2 ) exhibiting the highest levels of bioactivity were electrophoresed on denaturing polyacrylamide gels (10%) and evaluated by immunoblotting as described under "Experimental Procedures." Top panel, ␣-tubulin antibody (0.15 g/ml) and ␤-tubulin antibody (0.3 g/ml); rat brain membranes, 15 g of protein; NG108-15 membranes, 15 g of protein; NG108-15 membrane extract (pre-resin, 10 l), 20 g of protein; flowthrough from DEAE ion exchange resin, 10 l; elution 11 from DEAE ion exchange resin (NG108-15), 10 l. Center panel, antibody, 1 g/ml; rat brain membranes, 100 g of protein; NG108-15 membranes, 100 g of protein; NG108-15 membrane extract (pre-resin, 50 l), 100 g of protein; flow-through from DEAE ion exchange resin, 50 l; elution 11 from DEAE ion exchange resin (NG108-15), 50 l. Bottom panel, antisera dilution, 1:500; NIH-3T3 fibroblast membranes, 100 g of protein; PC-12 membrane extract (1% Thesit; 50 l), 100 g of protein; DDT 1 MF 2 membranes, 100 g of protein; NG108-15 membranes, 100 g protein; NG108-15 membrane extract (pre-resin, 50 l), 100 g of protein; flow-through from DEAE ion exchange resin, 50 l; elution 11 from DEAE ion exchange resin (NG108-15), 50 l. The protein concentration of the peak activity fraction was ϳ80 g/ml. pre-resin, solubilized material applied to the resin. post-resin, sample flow-through from the resin.
FIG. 8. Effect of the G-protein activator on the initial rate of [ 35 S]GTP␥S binding to brain G-protein in the presence of added GDP. The initial rate of GTP␥S binding to purified G-protein was determined over a range of [GTP␥S] as described under "Experimental
Procedures." A, NG108-15 membrane extracts eluted from the DEAE ion-exchange resin containing peak bioactivity (fractions 8 -14) were pooled, and 3. (Fig. 8) . The increased rate of [ 35 S]GTP␥S binding in the presence of the G-protein activator and GDP is compatible with an effect of the activator to facilitate dissociation of bound GDP.
The effect of the activator on [ 35 S]GTP␥S binding to brain G-protein was also determined in the absence of GDP (Fig. 9 ). In the presence or absence of GDP, the rate of [
35 S]GTP␥S binding to brain G-protein is linear over the incubation time evaluated, but in the absence of GDP, maximal [
35 S]GTP␥S binding was achieved within 10 min. At steady state in the absence of GDP, the amount of [ 35 S]GTP␥S binding to brain G-protein is similar whether or not the partially purified Gprotein activator is present in the assay system. However, the rate of binding to G-protein in the presence of activator could be resolved into two components and the G-protein activator altered the initial rate of nucleotide binding to G-protein (Fig. 9,  A and B) . In the presence of the NG108-15 G-protein activator, the rate of [
35 S]GTP␥S binding was increased by 4-fold during the first 30 s of incubation compared with that observed in the absence of added G-protein activator (Fig. 9, B and C) (Fig. 9A) . The rate of [ 35 S]GTP␥S binding from 45 s to 2.5 min without added GDP was similar in the presence or absence of G-protein activator (Fig. 9, B and C) . Thus in the absence of GDP, addition of the G-protein activator converted the early rate of [ 35 S]GTP␥S binding (from 0 to 2.5 min) into a biphasic association curve. The effect of the G-protein activator to cause an initial burst in the rate of nucleotide binding to G-protein was observed over a range of G-protein concentrations (Fig. 10) , and the magnitude of this activation was dependent on the amount of G-protein activator added to the incubation mixture (Fig. 11) . However, steady state nucleotide binding after the initial burst of activity depended upon G-protein concentration and was independent of the amount of activator added to the incubation mixture.
Effect of G-protein Activator on G oA and Free G␣-Membrane-bound hormone receptors activating G-proteins generally interact with the heterotrimeric form of G-protein and this issue was addressed for the G-protein activator isolated from NG108-15 cells. [
35 S]GTP␥S binding to brain G-protein, pure G oA , and free G␣ resolved from the brain G-protein preparation was determined in the presence and absence of the partially purified G-protein activator. G oA is the major G o heterotrimer found in the brain G-protein preparations. The effect of extract on nucleotide binding to the purified heterotrimer was similar   FIG. 9 . Effect of the G-protein activator on the initial rate of [ 35 S]GTP␥S binding to brain G-protein in the absence of added GDP. The initial rate of GTP␥S binding to purified G-protein was determined over a range of [GTP␥S] as described under "Experimental Procedures," except that GDP was not added to the incubation mixture. A, NG108-15 membrane extracts eluted from the DEAE ion-exchange resin containing peak bioactivity (fractions 8 -14) were pooled and 3.6 l of extract (closed circles) or vehicle (open circles) was preincubated with brain G-protein (final concentration ϭ 5 nM), and nucleotide binding was determined by the standard solution phase assay. The assay tube contained ϳ92,000 cpm (ϳ0.8 nM) or ϳ230,000 cpm (ϳ2 nM) [
35 S]GTP␥S and various concentration of added GTP␥S to obtain the desired concentration (indicated at the top left of the small boxes). The association of GTP␥S to brain G-protein was linear in the absence of the G-protein activator for the time period evaluated. In the presence of the G-protein activator, the curves illustrated in panel A were biphasic as indicated in panel B. C, the rate of GTP␥S binding to G-protein was calculated from the data presented in B as described under "Experimental Procedures." Similar results were obtained in three separate experiments.
to that observed with the bovine brain G-protein preparation (Fig. 12) . Surprisingly, the ability of the NG108-15 G-protein activator to increase nucleotide binding to brain G-protein in the presence of GDP did not require G␤␥ or an intact heterotrimer (Fig. 12) . In the presence of GDP, the effect of extract on nucleotide binding was similar at equimolar concentrations of G␣␤␥ or free G␣, and it was not affected by addition of G␤␥ to the G␣ preparation. There was also no apparent difference in the effect of the extract on G␣␤␥ versus G␣ over a range of G-protein concentrations (Table I) . DISCUSSION A number of diverse signaling mechanisms within the cell utilize guanine nucleotide-binding proteins as a molecular switch to propagate and amplify the biological signal. Key components of this molecular switch are the exchange of GDP for GTP and the GTPase activity inherent in the nucleotidebinding protein. Membrane receptors sensing external stimuli activate heterotrimeric G by facilitating nucleotide exchange and subsequent dissociation of G␤␥ and G␣. Such an event occurs with homogeneous preparations of receptor and G-protein following reconstitution in phospholipid vesicles, suggesting that the initiation of the cellular response to a biological stimuli involves only receptor and G-protein. However, the efficiency with which the receptor mediates the agonist-induced activation of G-protein is often dramatically less when the purified entities are reconstituted in phospholipid vesicles as compared with what is observed or expected to occur in the intact cell or membrane preparations. Such a discrepancy may reflect technical issues associated with reconstitution studies or the absence of other cellular factors required for driving this event. Although such a possibility is difficult to address, recent observations in cells transfected with genes encoding components of the signaling cascade or in unperturbed signaling systems endogenous to the cell suggest the existence of cellular 35 S]GTP␥S). B and C, in the absence of the G-protein activator, the association of GTP␥S to brain G-protein was linear for the time period evaluated, but the association curves for nucleotide binding in A were biphasic in the presence of the G-protein activator as indicated in B. C, the rate of GTP␥S binding to G-protein was calculated from the data generated in B as described under "Experimental Procedures." Similar results were obtained in two separate experiments.
FIG. 11. Effect of different amounts of the G-protein activator on the initial rate of [
35 S]GTP␥S to brain G-protein in the absence of added GDP. The initial rate of GTP␥S binding to purified G-protein was determined in the presence of increasing amounts of the G-protein activator. A, various amounts of pooled fractions eluted from the ion exchange matrix and containing peak bioactivity (closed symbols) or vehicle (open symbols) were preincubated with brain G-protein (final concentration ϭ 5 nM) as described under "Experimental Procedures." Except for the absence of GDP, the assay system was identical to that described in the legends to Figs. 1 and 2. Incubation conditions were as described in the legend to Fig. 9 . In the presence of the G-protein activator, the association rate of nucleotide was biphasic as indicated in A and B. C, the initial rate of GTP␥S binding to G-protein was calculated from the data generated in B as described under "Experimental Procedures". Similar results were obtained in two separate experiments.
factors that augment, direct, or brake the transfer of signal from receptor to G-protein (5) (6) (7) (8) (9) . Such a thought is given further impetus by the identification of proteins and chemical compounds that directly activate or inhibit G-proteins (12, 18, 21, 22, 32) . Recently, we suggested the existence of a cellspecific factor(s) that regulated the transfer of signal from receptor to G-protein and/or stimulated [ 35 S]GTP␥S binding to G-protein independent of receptor activation. Subsequent efforts, reported herein, involved the biochemical characterization of such a factor in the neuroblastoma glioma hybrid cell line NG108-15, its relationship to other known regulators of G-protein function, and the analysis of its functionality in sufficient detail as to allow its eventual isolation.
The G-protein activator extracted from NG108-15 membranes was heat-sensitive and was enriched by various chromatographic or fractionation procedures (ion exchange, size exclusion, and lectin affinity matrices) consistent with the properties of a protein molecule rather than a small organic molecule or lipid. The G-protein activator was enriched in the neuron-like cell lines PC-12 and NG108-15, but was absent in NIH-3T3 fibroblasts and the glioma cell line C6B4. These data suggested that the G-protein activator was enriched in neural tissue. Indeed a similar bioactivity was also observed following fractionation of detergent-solubilized membranes prepared from bovine brain. 4 In contrast to receptor-mediated activation of G-protein which prefers heterotrimeric G-protein, the G-protein activator augments nucleotide binding to G␣ in the absence of G␤␥ and functions in solution phase. The effect of the G-protein activator on nucleotide binding to resolved brain G␣ is not altered by addition of a 5-fold molar excess of G␤␥, suggesting that the activator interacts with G␣ at sites distinct from those interacting with the G␤␥ complex and it is unclear as to whether the heterotrimeric G-protein or free G␣ is a target for the activator in the cell. Although not certain as yet, the activator described in the present report may account for the cell type specific differences in receptor coupling to G-protein observed for the ␣ 2A/D -adrenergic receptor (5) . The activation of G-protein by the ␣ 2A/D -adrenergic receptor differs by 5-10-fold when the receptor is functioning in different microenvironments, even when the receptor accesses the same apparent population of G-protein (5). The augmented signal transfer from receptor to G-protein observed for the ␣ 2A/D -adrenergic receptor in PC-12 versus NIH-3T3 cells may reflect the existence of an additional "signal amplifier" in PC-12 cells (i.e. the G-protein activator described in the present report) or perhaps a factor in NIH-3T3 fibroblasts that impedes this event as postulated for the A 1 adenosine receptor (6) . Such entities may actually represent a family of proteins along the line of those recently termed "regulators of G-protein signaling" (7) (8) (9) .
Mechanistically, the effectiveness of the activator in the presence of GDP suggests that it acts to promote dissociation of GDP from G-protein, which would result in an accelerated rate of GTP binding to G-protein. However, its action is likely to be more complex, given its effects on the kinetics of GTP␥S binding to G-protein in the absence of GDP. In this case, the activator causes an initial burst of GTP␥S binding, followed by a slower steady state rate that is the same as that of G-protein in the absence of activator. The magnitude of the stimulation of the initial rate of GTP␥S binding was related to both G-protein and activator concentration, compatible with a simple bimolecular interaction between these two proteins that accounts for the stimulation. Since in the presence of GDP, the stimulation of GTP␥S by activator was linear with time, one might suggest that a GDP complex is essential for interaction between the 4 The detection of such an activity in crude bovine brain membrane extracts was complicated by the high background levels of nucleotide binding in the assay system, reflecting the high concentration of nucleotide-binding proteins in this tissue. To reduce the background signal, the solubilized membrane preparation from bovine brain was incubated with 10 M GTP␥S to saturate the nucleotide binding sites on endogenous G-proteins and subsequently fractionated by chromatofocusing or ion-exchange chromatography, which allowed the removal of unbound GTP␥S. Fractions eluted from the column were then evaluated in the assay system described under "Experimental Procedures" (M. Sato, J. D. Hildebrandt, and S. M. Lanier, unpublished results).
FIG. 12.
Effect of G-protein activator on G oA and free G␣. Fractions of NG108-15 membrane extracts eluted from the DEAE ionexchange resin containing peak bioactivity (fractions 8 -14) were pooled and used to determine the effect of the G-protein activator on free G␣ versus intact heterotrimers as described under "Experimental Procedures." G oA was purified from the bovine brain G-protein preparation by fractionation on a Mono-Q resin (26 -28) . Bovine brain G␣ was resolved from G␤␥ as described previously (26 -28) . Approximately 90% of the resolved G␣ was capable of binding [
35 S]GTP␥S. The effect of the G-protein activator (0.3 g of extract protein) on [
35 S]GTP␥S binding to G␣ or heterotrimeric G-protein was determined as described in the legends to Fig. 1 and 2 . Data are presented as the mean Ϯ S.E. of four experiments. activator and G-protein. The biphasic rates of GTP␥S binding observed in the presence of activator, but in the absence of GDP, indicate that there is a time-dependent change in the interaction of G-protein and stimulatory factor. During the early time points of GTP␥S association, the G-protein may exist in a particular conformation that is capable of interacting with the activator. However, this particular conformation is rapidly lost as incubation continues and thus the inability of the activator to influence steady state rates of GTP␥S binding. As the G-protein is purified in the GDP-liganded state, it is possible that the initial burst of nucleotide binding observed in the presence of activator is due to the interaction of the activator with the GDP-liganded G-protein. Upon dilution of G-protein into the incubation mixture without added GDP, the GDP dissociates from the majority of G-protein within the first minute and thus the activator does not influence the steady state rate of GTP␥S binding. Alternatively, if the activator functions as a catalytic entity, GDP may be required for recycling the activator and the initial burst observed in the absence of GDP represents one round of activator/G-protein/GDP complex. In either situation, the activator/G-protein/GDP complex would bind GTP␥S faster than would nucleotide-free G-protein, suggesting that the activator does more than just increase GDP dissociation. The G-protein activator characterized in the NG108-15 membrane extract is distinct from neuromodulin, ␤-amyloid precursor protein, tubulin, and caveolin: proteins that also directly influence nucleotide binding to G-proteins. Neuromodulin and ␤-amyloid precursor protein both associate with G o and augment nucleotide binding to purified heterotrimer (13, 16 -18, 32-34) . As is the case with the G-protein activator described in the present report, the action of neuromodulin is also independent of G␤␥ (18) . Tubulin is itself a guanine nucleotide-binding protein and is suggested to activate G s or G i1 by facilitating the exchange of GTP for GDP on G␣ (12, 19, 20) . Caveolins are actually a family of proteins (M r of ϳ 22,000) enriched in microdomains of the plasma membrane of various cell types, particularly endothelial cells (23, 24) . Recent reports indicate that these microdomains are also enriched in G-proteins and other molecules involved in signal transduction. Caveolin-1 and -2 associate with G o and inhibit GTPase activity (14) . Other types of caveolin may actually activate the heterotrimer (24) . Thus, neuromodulin, the caveolins, "regulators of G-protein signaling," and the G-protein accelerator described here may influence the strength of the signal initiated by activated receptor. Such molecules may contribute to the amplification of the biological stimuli commonly observed with signaling events involving heterotrimeric G-protein and may be of particular significance in tissues requiring rapid signal processing or under conditions of aberrant cell growth and development.
